Skip to content
Screener

Monopar Therapeutics MNPR Current ratio

Current ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.5×+0.3×
Eli Lilly logo
Eli LillyLLY
1.4×+0.1×
Bausch Health Companies logo
Bausch Health CompaniesBHC
1.3×0.0×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
1.7×-0.7×
Wave Life Sciences logo
Wave Life SciencesWVE
10×+7.4×
Prime Medicine logo
Prime MedicinePRME
3.1×-0.5×

Other financials

Income statement

See full
Revenue-—
Operating income-$5.2M-62.2%
Net income-$3.9M-48.3%
EPS (diluted)-$0.19—

Balance sheet

See full
Cash & equivalents$52.5M+32.3%
Total debt$230.4K+2,692%
Total equity$135.4M+153%
Total assets$138.0M+150%

Cash flow

See full
Operating cash flow-$3.5M+38.7%

Valuation

See full
Market cap$798.6M+317%
Enterprise value$746.28M+390%

Returns & leverage

See full
Return on equity-15.9%-6.6pp
Debt / equity0×0.0×

Where this comes from

Calculated from Monopar Therapeutics’s reported figures.

total current assets/total current liabilities=56×

Based on the most recent quarter.

The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 2:00 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001437749-26-016982

FAQ

What is Monopar Therapeutics's current ratio?
Monopar Therapeutics (MNPR) reported current ratio of 56× in Q1 2026.
What is the long-term trend for Monopar Therapeutics's current ratio?
Over 5 years (2020 to 2025), Monopar Therapeutics's current ratio has grown at a 29.2% compound annual growth rate (CAGR), from 14.3× to 51.4×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.

Ask your AI about Monopar Therapeutics's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude